​

 At Servo BioLabs, we are revolutionizing the fight against aging-related diseases by targeting harmful unfolded and misfolded proteins. Through groundbreaking research and development, we specialize in identifying and optimizing ERAD (Endoplasmic Reticulum-Associated Degradation) modulators to combat diseases such as type 2 diabetes, Alzheimer’s disease, and Parkinson’s disease.

​

 Our proprietary ERAD modulators have demonstrated remarkable potential in advancing human health. In pilot human studies, by reducing the Endoplasmic Reticulum (ER) stress in pancreatic beta cells, these modulators have not only enhanced the durability of existing oral type 2 diabetes treatments but, in many cases, have reversed the progression of the disease entirely.

​

 We are particularly proud to be the first to successfully harness natural plant extracts to enhance the efficiency of ERAD in eliminating misfolded insulin. This revolutionary approach offers a promising and sustainable strategy for reversing the effects of aging-related conditions, with type 2 diabetes being a key focus of our innovation.

 At Servo BioLabs, our mission is to lead the way in longevity science, delivering life-changing solutions that improve health and extend quality of life for individuals worldwide. With cutting-edge research and a commitment to natural, effective treatments, we are shaping the future of aging-related disease management.

​

Servo BioLabs – Transforming Science, Transforming Lives.